PBYI stock is the biggest loser in the biotech sector after Puma Biotechnology Inc. (NASDAQ:PBYI) reported disappointing revenue for its only commercial product, Nerlynx. Nevertheless, the company posted improved loss and revenue for the fiscal first quarter.
Nerlynx’s Revenue Spooks InvestorsThe biggest disappointment for PBYI stock investors is the company’s lower revenue for Nerlynx, compared to the previous quarter.
Puma Biotechnology reported a total revenue increase to $99 million, up from $67 million a year ago. The revenue was driven by Nerlynx sales, which is PBYI’s first commercial product. In Q1 2019, net ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.